Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
Eligible patients will receive XMT-1536 as an intravenous infusion once every four weeks. This is a dose escalation and expansion trial; patients in the dose escalation stage will receive increased doses of XMT-1536, until the patient(s) experience 2 or more dose-limiting events.
Conditions
This trial is treating people with cancers that express a specific gene (NaPi2b), such as ovarian cancer or non-small cell lung cancer
Eligibility
Inclusion
General Inclusion Criteria (for Dose Escalation, Expansion, and UPLIFT):
Ovarian Cancer Inclusion Criteria for UPLIFT:
- Histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent.
-
Platinum-resistant disease
- Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response [complete response/remission (CR) or partial response/remission (PR)], and then progressed between 3 months and ≤ 6 months after the date of the last dose of platinum
- Patients who have received 2 to 4 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum
-
One to 4 prior lines of systemic therapy for ovarian cancer
a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy
- Patients must be willing to provide an archival tumor tissue block or slides or if not available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically routine procedure
Ovarian Cancer Inclusion Criteria for QTc sub-study:
Note: patients must meet all UPLIFT cohort inclusion criteria in order to participate in the QTc sub-study
• Study patient has agreed to remain in the clinic for the additional QTc related study activities on the Day 1 of Cycle 1 and Cycle 3.
Exclusion
General Exclusion Criteria (for Dose Escalation, Expansion, and UPLIFT) :
- Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment, or recent radiation therapy with unresolved toxicity or within a time window of potential toxicity.
- Patients with untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
- Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
- Prior history of liver disease such as liver cirrhosis, hepatic fibrosis
- Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations.
- Current use of either constant or intermittent supplementary oxygen therapy.
- History of suspected pneumonitis or interstitial lung disease.
- Pregnant or nursing women.
- History of other malignancy within the last 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
- Active corneal disease, or history of corneal disease within 12 months prior to enrollment
- Use of strong CYP450 3A inhibitors or inducers that cannot be discontinued while receiving study treatment
- Oxygen saturation on room air <93%
Ovarian Cancer Exclusion Criteria for UPLIFT:
- Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed histology, or stromal tumors
- Prior treatment with mirvetuximab soravtansine or another ADC containing an antitubulin payload
- Primary platinum-resistant disease, defined by a lack of response or by progression within 3 months after completing front-line, platinum-containing therapy.
- Participation in DES or EXP segments of this study
Ovarian Cancer Exclusion Criteria for QTc sub-study:
- Use of strong CYP450 3A inducers.
- Uncontrolled cardiac arrhythmias, for example, atrial fibrillation with a ventricular response at rest > 100 beats per minute. left bundle branch block (LBBB)
- Known abnormality of any cardiac valve (either stenosis or regurgitation) that is greater than moderate in severity.
- Subjects not in sinus rhythm at screening with HR >45- <100
- Any ECG abnormality that can interfere with the measurement of the QT interval
Inclusion
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Mersana Therapeutics
Scientific Title
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information